Our findings demonstrate that NAFLD mice do convert a portion of cholesterol into BAs via CYP7A1 and CYP27A1, but the rate of lipid degradation is considerably lower than that observed with a high-dose PPE intervention. This evidence concerns the gene CYP7A1 and metabolic dysfunction-associated steatotic liver disease.